Aridis Pharmaceuticals Stock

Aridis Pharmaceuticals Dividend 2025

Aridis Pharmaceuticals Dividend

0 USD

Aridis Pharmaceuticals Dividend yield

Ticker

ARDS

ISIN

US0403341045

WKN

A2N38H

How much dividend does Aridis Pharmaceuticals 2025 pay?

According to the latest status from August 2025, Aridis Pharmaceuticals paid a total of 0 USD per share in dividends within the last 12 months. With the current Aridis Pharmaceuticals price of 0 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Aridis Pharmaceuticals Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Aridis Pharmaceuticals Dividend Safe?

Aridis Pharmaceuticals has been increasing the dividend for 0 years.

Over the past 8 years, Aridis Pharmaceuticals has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Aridis Pharmaceuticals's Dividend Distributions

Aridis Pharmaceuticals’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Aridis Pharmaceuticals's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Aridis Pharmaceuticals's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Aridis Pharmaceuticals’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Aridis Pharmaceuticals Aktienanalyse

What does Aridis Pharmaceuticals do?

Aridis Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of immunotherapeutics and antibiotics for the treatment of infectious diseases. It was founded in 2003 in San Jose, California. The company's business model aims to address the gap in the infectious disease market caused by antibiotic resistance and the lack of new therapy options. Aridis has developed several patented technologies that allow for the quick and effective identification of potential candidates for new therapies. The company focuses on antibiotic development, utilizing a library of human monoclonal antibodies targeted specifically for infectious diseases. These antibodies can be used to target bacteria and achieve better efficacy against antibiotic resistance. Aridis has promising candidates in clinical development. The company also focuses on the development of immunotherapeutics for infectious diseases. They have developed a portfolio of monoclonal antibodies that target pathogenic microbes and can activate immune cells to strengthen the body's immune system. Some of Aridis' key products include Aerucin for the treatment of pneumonia and other respiratory diseases, and AR-101 for severe infections caused by Pseudomonas aeruginosa. Both products are currently in Phase II of development. Another important product is AR-301, a monoclonal antibody developed for the treatment of severe Staphylococcus infections. AR-301 has successfully completed Phase IIb studies and is currently undergoing accelerated approval by the US Food and Drug Administration (FDA). Aridis has formed collaborations with academic institutions and other biopharmaceutical companies to access the latest scientific knowledge and technologies. They have partnerships with multiple universities and research institutes worldwide. The company has also partnered with AmpliPhi Biosciences for the development of bacteriophage-based therapies for infectious diseases, and with Mount Sinai Health System for the development of immunotherapeutics for respiratory diseases. Overall, Aridis has a strong position in the infectious disease market and is well-positioned to address the gap caused by antibiotic resistance and the lack of new therapies. With a strong portfolio of patented technologies, promising candidates in clinical development, and broad partnerships, the company has the potential to become a leading player in the industry. Aridis Pharmaceuticals is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Aridis Pharmaceuticals stock

How much dividend does Aridis Pharmaceuticals pay?

Over the past 12 months, Aridis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aridis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aridis Pharmaceuticals?

The current dividend yield of Aridis Pharmaceuticals is .

When does Aridis Pharmaceuticals pay dividends?

Aridis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aridis Pharmaceuticals?

Aridis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aridis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aridis Pharmaceuticals located?

Aridis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aridis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aridis Pharmaceuticals from 8/2/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/2/2025.

When did Aridis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/2/2025.

What was the dividend of Aridis Pharmaceuticals in the year 2024?

In the year 2024, Aridis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aridis Pharmaceuticals pay out the dividend?

The dividends of Aridis Pharmaceuticals are distributed in USD.

Andere Kennzahlen von Aridis Pharmaceuticals

Our stock analysis for Aridis Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aridis Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.